256 related articles for article (PubMed ID: 36106755)
21. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment.
Nicolatou-Galitis O; Schiødt M; Mendes RA; Ripamonti C; Hope S; Drudge-Coates L; Niepel D; Van den Wyngaert T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2019 Feb; 127(2):117-135. PubMed ID: 30393090
[TBL] [Abstract][Full Text] [Related]
22. Management of Medication-Related Osteonecrosis of the Jaw.
Williams WB; O'Ryan F
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):517-25. PubMed ID: 26515735
[TBL] [Abstract][Full Text] [Related]
23. [Progress on medication-related osteonecrosis of the jaw].
Wang QZ; Liu JY; Pan J
Hua Xi Kou Qiang Yi Xue Za Zhi; 2018 Oct; 36(5):568-572. PubMed ID: 30465354
[TBL] [Abstract][Full Text] [Related]
24. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Fusco V; Campisi G; Bedogni A
Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
[TBL] [Abstract][Full Text] [Related]
25. A 5-year retrospective cohort study of denosumab induced medication related osteonecrosis of the jaw in osteoporosis patients.
Jung S; Kim J; Park JH; Kim KY; Kim HJ; Park W
Sci Rep; 2022 May; 12(1):8641. PubMed ID: 35606457
[TBL] [Abstract][Full Text] [Related]
26. Medication-related osteonecrosis of the jaw: A literature review.
Kuroshima S; Sasaki M; Sawase T
J Oral Biosci; 2019 Jun; 61(2):99-104. PubMed ID: 31109863
[TBL] [Abstract][Full Text] [Related]
27. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
28. Update MRONJ and perspectives of its treatment.
Voss PJ; Poxleitner P; Schmelzeisen R; Stricker A; Semper-Hogg W
J Stomatol Oral Maxillofac Surg; 2017 Sep; 118(4):232-235. PubMed ID: 28697987
[TBL] [Abstract][Full Text] [Related]
29. A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis.
Campisi G; Mauceri R; Bertoldo F; Fusco V; Bedogni A
Head Face Med; 2021 Jul; 17(1):25. PubMed ID: 34243807
[TBL] [Abstract][Full Text] [Related]
30. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients.
Boston B; Ipe D; Capitanescu B; Gresita A; Hamlet S; Love R; Hadjiargyrou M; Huang CL; Nusem I; Miroiu RI; Popa-Wagner A; Warnke PH; Petcu EB
J Am Geriatr Soc; 2023 Aug; 71(8):2640-2652. PubMed ID: 37224415
[TBL] [Abstract][Full Text] [Related]
31. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw.
Obermeier KT; Dewenter I; Malenova Y; Fliefel R; Kaeppler G; Otto S
Sci Rep; 2024 Apr; 14(1):7914. PubMed ID: 38575664
[TBL] [Abstract][Full Text] [Related]
32. Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw.
Allegra A; Innao V; Pulvirenti N; Musolino C
Tohoku J Exp Med; 2019 May; 248(1):27-29. PubMed ID: 31080196
[TBL] [Abstract][Full Text] [Related]
33. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
34. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
[TBL] [Abstract][Full Text] [Related]
35. The Prevention of Medication-related Osteonecrosis of the Jaw.
Poxleitner P; Engelhardt M; Schmelzeisen R; Voss P
Dtsch Arztebl Int; 2017 Feb; 114(5):63-69. PubMed ID: 28241916
[TBL] [Abstract][Full Text] [Related]
36. Medication-Related Osteonecrosis of the Jaw (MRONJ): Are Antiresorptive Drugs the Main Culprits or Only Accomplices? The Triggering Role of Vitamin D Deficiency.
Dalle Carbonare L; Mottes M; Valenti MT
Nutrients; 2021 Feb; 13(2):. PubMed ID: 33567797
[TBL] [Abstract][Full Text] [Related]
37. Infection and medication-related osteonecrosis of the jaw.
Katsarelis H; Shah NP; Dhariwal DK; Pazianas M
J Dent Res; 2015 Apr; 94(4):534-9. PubMed ID: 25710950
[TBL] [Abstract][Full Text] [Related]
38. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab.
Wick A; Bankosegger P; Otto S; Hohlweg-Majert B; Steiner T; Probst F; Ristow O; Pautke C
Clin Oral Investig; 2022 Mar; 26(3):2839-2852. PubMed ID: 34812959
[TBL] [Abstract][Full Text] [Related]
39. Case series of medication-related osteonecrosis of the jaw (MRONJ) patients prescribed a drug holiday.
Hamid A; Thomas S; Bell C; Gormley M
Br J Oral Maxillofac Surg; 2023 Apr; 61(3):227-232. PubMed ID: 36935312
[TBL] [Abstract][Full Text] [Related]
40. Medication-related osteonecrosis of the jaw: A multifaceted diagnostic challenge. Mini review.
Bonachea R; Katz J
Am J Dent; 2022 Apr; 35(2):109-112. PubMed ID: 35506967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
